• Title/Summary/Keyword: phosphodiesterase

Search Result 219, Processing Time 0.038 seconds

Antifibrotic Effects of Phosphodiesterase (PDE) Inhibitor in Experimental Interstitial Fibrosis induced by Unilateral Ureteral Obstruction. (일측성 요로폐쇄에 의한 실험적 신 간질 섬유화에서 Phosphodiesterase(PDE) 억제제의 항 섬유화 작용)

  • Ha Il Soo;Um Eun Young;Kang Hee-Gyung;Hahn Hye Won;Park Hye Won;Cheong Hae Il;Choi Yong
    • Childhood Kidney Diseases
    • /
    • v.6 no.1
    • /
    • pp.85-91
    • /
    • 2002
  • Purpose: Phosphodiesterase (PDE) inhibitor increases the cellular content of cAMP, and cAMP suppresses connective tissue growth factor (CTGF) expression induced by TGF-${\beta}1$. Therefore, we investigated whether PDE inhibitor suppresses renal fibrosis without suppression of TGF-${\beta}1$. Materials and Methods : Renal interstitial fibrosis was produced by ligation of left ureter in Sprague-Dawley rats. Cilostazol, a selective PDE3 inhibitor, and dipyridamole, a hybrid PDE5, PDE6, and PDE8 inhibitor, were provided in drinking water for 7 days. In addition to the Masson-trichrome score of renal tissue, the concentration of fibronectin and TGF-${\beta}1$ in renal tissue- conditioned media was measured by ELISA. Results : Masson- trichrome score and fibronectin concentration were significantly lower in cilostazol-treated group compared to the control group (P<0.05). Though dipyridamole treatment seemed to suppress the Masson- trichrome score and fibronectin concentration too, the decrements were not statistically significant. There was no difference in TGF-${\beta}1$ concentration among the groups. Conclusion: A selective PDE3 inhibitor cilostazol suppresses renal fibrosis without alteration of TGF-${\beta}1$ expression. (J Korean Soc Pediatr Nephrol 2002 ;6 : 85-91)

  • PDF

Phosphodiesterase Inhibitor 인 KR30289의 대사연구

  • 김동현;박미숙;이향숙;박종세
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 1994.04a
    • /
    • pp.272-272
    • /
    • 1994
  • 신약개발에 있어서 대사연구는 약효의 species difference, 독성기전, 그리고 in vitro와 in vivo의 약효차이를 이해하는데 매우 중요한 역할을 담당하며 그 연구 영역을 넓혀가고 있다. 본 연구에서는 항혈전제로 개발 가능성이 있는 phosphodiesterase inhibitor인 KR30289의 rat과 rabbit에서 대사 연구를 통하여 약리효과의 상이점을 밝히고져 하였다. Mass analysis를 통하여 urinary 대사체의 구조를 규명한 결과 KR30289를 경구 투여 (1mg/kg)시 hydroxy derivative(M1)와 O-dealkylated derivative(M2)로 변환되어 urine으로 배설되었고 parent compound는 검출되지 않았다 M1과 M2 모두 free form, glucuronide conjugate, 그리고 sulfate conjugate 형태로 검출되었으나 rat과 rabbit 두 종간의 M1과 M2의 비율에서는 커다란 차이점을 보여주었다 rat의 경우 M2가 94% (free form : 14%, glucuronide conjugate 58%. sulfate conjugate, 22%)이었으며 rabbit에서는 M1이 54%로 상대적으로 많이 생성되었다(free form : 11%, glucuronide conjugate : 22%, sulfate conjugate 21%). 이와같이 두종간의 상이한 metabolic profile로 인하여 약리효과의 차이가 유발될수 있다고 추론된다.

  • PDF

Inhibitory Action of Phenylpropanoids on Phospholipase A2 and Phosphodiesterase in Athmatic Guinea Pig Lung

  • Kim, Youn-Joung;Lee, Ji-Yun;Lee, Jin-Hee;Kim, Tae-Doo;Sim, Sang-Soo;Kim, Chang-Jong
    • Proceedings of the PSK Conference
    • /
    • 2003.04a
    • /
    • pp.193.2-194
    • /
    • 2003
  • Effect of phenylpropanoids on Phospholipase A2 (PLA2) and phosphodiesterase (PDE) activities in the asthmatic lung tissue were studied in guinea pigs. Bronchial asthma were introduced by the challenge of aerosolized ovalbumin (OA) in the double-chambered plethysmograph at twenty one days after sensitization of OA in guinea pigs. Bronchoalveolar lavage fluids (BALF) were taken by brochalveolar lavage with HEPES buffer. (omitted)

  • PDF

COMPARISON OF EMETIC POTENTIAL INDUCED BY PDE IV INHIBITORS IN THE FERRET

  • Park, Jae-Mook;Lee, Sung-Hak;Kim, Il-Hwan;Yeon, Kyu-Jeong;Kim, Dal-Hyun
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2002.05a
    • /
    • pp.114-114
    • /
    • 2002
  • Inhibitors of type IV phosphodiesterase (PDE IV) are currently being developed as new therapeutic agents for asthma, chronic obstructive pulmonary disease(COPD) and arthritis. Unfortunately, the anti-inflammatory effect of PDE IV inhibitors has been considered to be associated to some extent with vomiting as adverse effect. The first generation PDE IV inhibitor, rolipram, was known to induce emesis at clinical trials. (omitted)

  • PDF

Subacute toxicities and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs

  • Junghee Han;Cha, Shin-Woo;Im, Doo-Hyun;Chung, Moon-Koo
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2003.05a
    • /
    • pp.43-44
    • /
    • 2003
  • The subacute toxicity and toxicokinetics of a type IV phosphodiesterase inhibitor, CJ-10882, were evaluated after single (on the 1st day) and 4-week (on the 27th day) oral administration of the drug, in doses of 0 (to serve as a control), 2, 10 and 50 mg/kg/d, to male and female dogs (n = 3 for male and female dogs for each dose). During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross findings, organ weight and histopathology were examined.(omitted)

  • PDF

Regulatory Effects of Cyclic AMP on Osteoclast Formation (조골세포내 cAMP 농도 변화가 파골세포 형성에 미치는 영향)

  • Chun Yunna;Yim Mijung
    • YAKHAK HOEJI
    • /
    • v.49 no.1
    • /
    • pp.109-113
    • /
    • 2005
  • In the present study treatment of IBMX, a phosphodiesterase (PDE) inhibitor, alone induced osteoclast formation in co-cultures of mouse bone marrow cells and calvarial osteoblasts. However, treatment of IBMX in combination with prostaglandin $E_2\;(PGE_2)$ inhibited osteoclast formation in a dose-dependent manner. Among various isozyme-specific PDE inhibitors, a PDE4 specific inhibitor, rolipram, showed similar effects as IBMX on osteoclast formation. To address the involvement of cyclic adenosine monophosphate (cAMP) in osteoclast formation, cAMP concentration in calvarial osteoblasts was investigated. When calvarial osteoblasts were co-cultured with IBMX alone or in combination with $PGE_2$, the patterns of cAMP concentration in calvarial osteoblasts were differ each other suggesting that cAMP in calvarial osteoblasts subtly regulates osteoclast formation.

Synthesis and Biological Studies of Catechol Ether Type Derivatives as Potential Phosphodiesterase (PDE) IV Inhibitors

  • Rhee, Chung K.;Kim, Jong-Hoon;Suh, Byung-Chul;Xiang, Myung-Xik;Youn, Yong-Sik;Bang, Won-Young;Kim, Eui-Kyung;Shin, Jae-Kyu;Lee, Youn-Ha
    • Archives of Pharmacal Research
    • /
    • v.22 no.2
    • /
    • pp.202-207
    • /
    • 1999
  • New series of catechol ether type derivatives 5, 6 have been synthesized and applied to biological tests. Even though it is ap preliminary data, some of our target molecules show the promising result against PDE IV inhibition. SAR and biological studies with studies with synthetic compounds will be discussed in detail.

  • PDF

Synthesis and Biological Studies of A Novel Series of Catechol Ether Type Derivatives as Potential Phosphodiesterase(PDE) IV Inhibitors

  • Lee, Jae-Mok;Lee, Koun-Ho;Kim, Jong-Hoon;Song, Seog-Beom;Chun, Hyung-Ok;Yeon, Kyu-Jeong;Kwon, Soon-Ji
    • Proceedings of the PSK Conference
    • /
    • 2002.10a
    • /
    • pp.348.1-348.1
    • /
    • 2002
  • We synthesized various catechol ether type derivatives substituted by the hydrazine moiety and evaluated for their ability to inhibit PDE Ⅳ (Phosphodiesterase Ⅳ). These new compounds were synthesized from 4-methoxy-3-hydroxy benzaldehyde through 5 or 7 steps. Some of them have similar or more potent inhibitory activity against PDE Ⅳ than known PDE Ⅳ inhibitor. Ariflo (SB 207499). Structure activity relationship (SAR) and biological studies of described compounds will be discussed in detail. (omitted)

  • PDF